Parkside Financial Bank & Trust’s First Tracks Biotherapeutics TRAX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$503	Buy	+25	New	+$467	﹤0.01%	2597

Other funds holding TRAX

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Parkside Financial Bank & Trust's TRAX Position: Q2 2026 in Review

Parkside Financial Bank & Trust opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 25 shares worth $503. The stake represents ﹤0.01% of the portfolio and ranks #2597 among its holdings.

150 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

Parkside Financial Bank & Trust held 25 shares of First Tracks Biotherapeutics worth $503 as of Q2 2026.
First Tracks Biotherapeutics was a new Parkside Financial Bank & Trust position in Q2 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2597 holding.
150 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.